08 September 2021 | NewsCOVID-19 Delta variant in schools and early childhood education and care services in NSW, Australia: 16 June to 31 July 2021Read the full article
AstraZeneca COVID-19 vaccine Vaxzevria is associated with a very rare risk of a condition called thrombosis with thrombocytopenia syndrome, or TTS.
TTS involves blood clots (thrombosis) along with low platelet levels (thrombocytopenia), and occurs around 4-28 days after vaccination. It is currently estimated to affect around 6 people per million doses. To date, almost all reported cases were after the first dose of the vaccine.
Several resources are available to provide information to immunisation providers about TTS following vaccination with COVID-19 Vaccine AstraZeneca.
We have answered commonly asked questions about thrombosis with thrombocytopenia syndrome following COVID-19 Vaccine AstraZeneca on our COVID-19 vaccines: Frequently asked questions webpage. Access these and other questions and answers about COVID-19 vaccines here.
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Copyright © 2021 NCIRS. All rights reserved
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS